Provider review
Enhance MD review
Publishes the whole ladder, including a separate low tirzepatide tier.
Every tier is listed up front and priced flat within itself, so starting low inside a tier costs no more.
Price as published
Compounded semaglutide $212/mo (first month $112) · tirzepatide $280/mo · tirzepatide microdose $169/mo · sema+tirz combo $322/mo · optional NAD+
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The verdict
Enhance MD puts its entire price ladder on the page — semaglutide, standard tirzepatide, a low-dose tirzepatide tier and a combination tier — which is rarer than it should be among compounders, and it builds periodic metabolic lab testing into ongoing care rather than treating labs as an add-on. Within each tier the price is flat, so starting at the bottom of a tier costs nothing extra. It is compounded-only with no brand-name or oral route, and it does not publish which states it serves, so eligibility is the first thing to confirm.
The trade-off we would want you to read first
The states it operates in are not published, so you must confirm eligibility before starting
Who it suits, and who it does not
A good fit if
- You want to see every tier and its price before you hand over any details
- You want lab monitoring included in the programme rather than arranged yourself
- You want a low tirzepatide tier that is priced below the standard one
Look elsewhere if
- You want a brand-name or oral pathway — neither exists here
- You need to confirm state availability before starting: it is not published
- You are shopping purely on entry price once any first-month discount ends
How the programme works
Enhance MD is a compounded-only GLP-1 telehealth practice that publishes its full price ladder up front: semaglutide at $212/mo (a discounted $112 first month), standard tirzepatide at $280/mo, a low-dose tirzepatide microdose at $169/mo, and a semaglutide+tirzepatide combination at $322/mo, with an optional NAD+ add-on. Dosing is flat within each tier, an online intake is reviewed by a provider, and the program builds in metabolic lab testing roughly every six months as part of ongoing care.
At a glance
- Pricing structure
- Varies by dose, plan or tier
- Consult
- Included in the price
- Compounding
- Not publicly identified
- Labs
- Required
- Dietitian support
- Not included
Strengths
- Fully transparent tiered pricing, including a low microdose tirzepatide tier at $169/mo
- Dose-flat within each tier, so starting low does not cost more per tier
- Built-in metabolic lab testing (about every 6 months) with provider oversight
- NAD+ adjacency for patients combining metabolic and longevity protocols
The other trade-offs
- Compounded-only — no brand-name or oral pathway, and compounded GLP-1s are not FDA-approved
- Higher entry price than the cheapest microdose options here once the first-month discount ends
- Like all intentional GLP-1 microdosing, the approach is off-label and unproven
Before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomised trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
Where this sits on the board
Enhance MD is one of 24 low-dose GLP-1 providers we track. The board lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Funding & disclosures
- A number of links are affiliate or referral links.
- Begin treatment through one and we may earn a commission via the Katalys network — at no added cost to you.
- What we write about a provider is the same either way — unflattering findings about one that pays us stay in.
- Full detail: disclosure page.